SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA's upcoming earnings are a major market focus, with some believing the entire market's direction hinges on the results, especially given the recent AI sector pullback. Community discussions range from expectations of a blowout report to fears of a post-earnings sell-off, with some suggesting the AI narrative may be overhyped, while others point to strong demand and potential for growth.

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Limited - ADR

Kazia Therapeutics

KZIA is trending due to promising early results from a Phase 1b trial combining Paxalisib with Keytruda and chemotherapy for triple-negative breast cancer, showing a significant reduction in tumor cells. The community is discussing the potential of this combination therapy and its implications for future cancer treatments. Some investors are closely monitoring the low float, potential for a short squeeze, and upcoming data releases, while others express caution due to the company's financial situation and past stock behavior.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending as community members discuss the company's recent earnings report, with attention focused on its project pipeline and revenue guidance. Debate centers on the company's cash position, the validity and timing of contracts, and the potential impact of AI-related projects. Analyst ratings and potential buybacks are also being closely watched by investors.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss its potential role in securing critical mineral supplies amid geopolitical tensions and the reopening of government operations; the community is weighing in on the company's value and potential catalysts, such as government approvals and strategic partnerships, while navigating market volatility.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet ($STRK) is trending due to increasing BTCFi staking, with mentions of over 1,000 BTC secured on-chain and incentives driving network growth; the community is also buzzing about Starknet's quantum-resistant technology and potential integration with ZCash ($ZEC) for enhanced privacy, leading to speculation about a significant rally.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Olema Pharmaceuticals Inc

Olema Pharmaceuticals is trending due to Roche's positive Phase 3 results for a similar breast cancer therapy, boosting investor confidence in Olema's lead drug. Community discussions revolve around potential short squeezes, analyst upgrades, and speculation about a possible buyout from larger pharmaceutical companies. However, some traders are wary of a potential offering and are taking profits, while others are looking for entry points for a short position.

Based Chad

$CHAD is trending as community members highlight the potential for a supply shock and the upcoming release of a video game, driving bullish sentiment. Discussion also focuses on the association with Coinbase, noting executives' apparent interest in the meme coin. Community members suggest that $CHAD is outperforming other memecoins.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending as investors discuss the company's dry eye drug portfolio, particularly VEVYE's potential, and the recent closing of the MELT acquisition, anticipating a PR soon. Community members are weighing in on revenue potential from various drugs and the impact of recent acquisitions, with many expressing bullish long-term views despite short-term volatility. There's also discussion around a potential pullback to buy more shares before Q3 earnings, driven by confidence in Harrow's long-term growth in the ophthalmic market.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as investors assess the potential impact of Nvidia's upcoming earnings report amid broader concerns about an AI bubble and recent market volatility. Community discussions revolve around possible market reactions to the report, with some anticipating a significant swing while others remain cautious. Broader market factors, such as potential interest rate cuts and economic data, add to the uncertainty surrounding QQQ's near-term performance.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is trending as the crypto community debates its potential amid discussions around AAVE's new savings app and broader altcoin market performance. Some investors express concerns about COMP's fundamentals and potential treasury issues, while others remain optimistic, citing its low downside risk and potential for a pump when ETH moves up.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ALYI I would think folks would start gobbling it up at this price. 🤞

Emil Geosits

James Mesich

Christo

Andrew

StockTwits for iOS

Alternet Systems, Inc.

 I would think folks would start gobbling it up at this price. 🤞

@Gonefishin365 There just isn&#39;t much reason to right now. They just reported 2 million in revenue for a quarter which does not seem to match up with the company on their website.  
 
Management does not seem interested in defending the share price by putting out more information. Something has to change before anyone has any sense of urgency about this company.

StockTwits Web

 There just isn't much reason to right now. They just reported 2 million in revenue for a quarter which does not seem to match up with the company on their website.  
 
Management does not seem interested in defending the share price by putting out more information. Something has to change before anyone has any sense of urgency about this company.